Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
<p>Abstract</p> <p>Background</p> <p>Malignant gliomas recur even after extensive surgery and chemo-radiotherapy. Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-08-01
|
| Series: | World Journal of Surgical Oncology |
| Online Access: | http://www.wjso.com/content/5/1/89 |
| _version_ | 1819039914160816128 |
|---|---|
| author | Arai Hajime Matsuno Akira Ishii Hisato Fujimaki Takamitsu Nakagomi Tadayoshi |
| author_facet | Arai Hajime Matsuno Akira Ishii Hisato Fujimaki Takamitsu Nakagomi Tadayoshi |
| author_sort | Arai Hajime |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Malignant gliomas recur even after extensive surgery and chemo-radiotherapy. Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only a few months and drug resistance develops thereafter in most cases. Induction of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) in tumors is considered to be responsible for resistance to TMZ. Interferon-beta has been reported to suppress MGMT in an experimental glioma model. Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.</p> <p>Case presentation</p> <p>A patient with recurrent AA after radiation-chemotherapy and stereotactic radiotherapy was treated with TMZ. After 6 cycles, the tumor became refractory to TMZ, and the patient was treated with interferon-beta at 3 × 10<sup>6 </sup>international units/body, followed by 5 consecutive days of 200 mg/m<sup>2 </sup>TMZ in cycles of 28 days. After the second cycle the tumor decreased in size by 50% (PR). The tumor showed further shrinkage after 8 months and the patient's KPS improved from 70% to 100%. The immunohistochemical study of the initial tumor specimen confirmed positive MGMT protein expression.</p> <p>Conclusion</p> <p>It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy.</p> |
| first_indexed | 2024-12-21T09:00:46Z |
| format | Article |
| id | doaj.art-093fd9ac340b4bb08b6d2b887a550e8a |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-12-21T09:00:46Z |
| publishDate | 2007-08-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-093fd9ac340b4bb08b6d2b887a550e8a2022-12-21T19:09:28ZengBMCWorld Journal of Surgical Oncology1477-78192007-08-01518910.1186/1477-7819-5-89Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytomaArai HajimeMatsuno AkiraIshii HisatoFujimaki TakamitsuNakagomi Tadayoshi<p>Abstract</p> <p>Background</p> <p>Malignant gliomas recur even after extensive surgery and chemo-radiotherapy. Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only a few months and drug resistance develops thereafter in most cases. Induction of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) in tumors is considered to be responsible for resistance to TMZ. Interferon-beta has been reported to suppress MGMT in an experimental glioma model. Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.</p> <p>Case presentation</p> <p>A patient with recurrent AA after radiation-chemotherapy and stereotactic radiotherapy was treated with TMZ. After 6 cycles, the tumor became refractory to TMZ, and the patient was treated with interferon-beta at 3 × 10<sup>6 </sup>international units/body, followed by 5 consecutive days of 200 mg/m<sup>2 </sup>TMZ in cycles of 28 days. After the second cycle the tumor decreased in size by 50% (PR). The tumor showed further shrinkage after 8 months and the patient's KPS improved from 70% to 100%. The immunohistochemical study of the initial tumor specimen confirmed positive MGMT protein expression.</p> <p>Conclusion</p> <p>It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy.</p>http://www.wjso.com/content/5/1/89 |
| spellingShingle | Arai Hajime Matsuno Akira Ishii Hisato Fujimaki Takamitsu Nakagomi Tadayoshi Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma World Journal of Surgical Oncology |
| title | Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma |
| title_full | Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma |
| title_fullStr | Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma |
| title_full_unstemmed | Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma |
| title_short | Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma |
| title_sort | effectiveness of interferon beta and temozolomide combination therapy against temozolomide refractory recurrent anaplastic astrocytoma |
| url | http://www.wjso.com/content/5/1/89 |
| work_keys_str_mv | AT araihajime effectivenessofinterferonbetaandtemozolomidecombinationtherapyagainsttemozolomiderefractoryrecurrentanaplasticastrocytoma AT matsunoakira effectivenessofinterferonbetaandtemozolomidecombinationtherapyagainsttemozolomiderefractoryrecurrentanaplasticastrocytoma AT ishiihisato effectivenessofinterferonbetaandtemozolomidecombinationtherapyagainsttemozolomiderefractoryrecurrentanaplasticastrocytoma AT fujimakitakamitsu effectivenessofinterferonbetaandtemozolomidecombinationtherapyagainsttemozolomiderefractoryrecurrentanaplasticastrocytoma AT nakagomitadayoshi effectivenessofinterferonbetaandtemozolomidecombinationtherapyagainsttemozolomiderefractoryrecurrentanaplasticastrocytoma |